Munich Cancer Registry



- Incidence and Mortality
- Selection Matrix
- Homepage
- Deutsch

ICD-10 C76-C80: Secondary and unspecified sites



Survival

Munich Cancer Registry Cancer Registry Bavaria - Upper Bavaria Regional Center at Klinikum Grosshadern/IBE Marchioninistr. 15 Munich, 81377 Germany

https://www.tumorregister-muenchen.de/en

https://www.tumorregister-muenchen.de/en/facts/surv/sC7680E-ICD-10-C76-C80-Secondary-and-unspecified-sites-survival.pdf

Index of figures and tables

Fig./Tbl.	Page
1a Relative survival by period of diagnosis (chart)	3
1b Survival by period of diagnosis (table)	3
2a Survival by sex (chart)	4
2b Survival by sex (table)	4
2c Conditional survival by sex (chart)	5
2d Conditional survival by sex (table)	5
3a Observed survival by age category (chart)	6
3b Relative survival by age category (chart)	6
3c Survival by age category (table)	7
4a Relative survival by extent of disease (chart)	8
4b Survival by extent of disease (table)	8




Figure 1a. Relative survival of patients with Secondary and unspecified sites by period of diagnosis. Included in the evaluation are 5,142 cases diagnosed between 1988 and 2020.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from to, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	F	gnosis	S				
	1988-	1988-1997		1998-2006		2007+	
	n=6	622	n=1,	601	n=2,919		
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	100.0	100.0	
1	38.5	39.7	34.1	35.3	37.0	38.3	
2	25.9	27.3	22.1	23.5	26.2	27.7	
3	19.8	21.5	16.5	18.0	21.4	23.3	
4	16.7	18.6	13.8	15.3	19.1	21.3	
5	14.7	16.8	12.3	14.1	17.4	20.0	
6	12.9	15.1	11.6	13.5	16.4	19.2	
7	12.2	14.7	10.1	12.1	15.5	18.7	
8	11.5	14.1	9.3	11.3	14.4	17.8	
9	10.8	13.6	8.9	11.0	13.6	17.3	
10	10.1	12.9	8.1	10.3	12.5	16.3	
Median	0.6		0.5		0.5		

Table 1b. Observed (obs.) and relative (rel.) survival of patients with Secondary and unspecified sites by period of diagnosis for period 1988-2020 (N=5,142).




Figure 2a. Survival of patients with Secondary and unspecified sites by sex. Included in the evaluation are 4,520 cases diagnosed between 1998 and 2020.

	Sex				
	Ma	ale	Fen	nale	
	n=2,	389	n=2,131		
Years	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	
1	36.1	37.3	35.8	37.2	
2	25.7	27.2	23.5	25.1	
3	20.3	22.1	18.9	20.6	
4	18.0	20.0	16.2	18.1	
5	16.2	18.5	14.7	17.0	
6	15.1	17.7	14.0	16.5	
7	13.9	16.7	12.9	15.5	
8	13.0	16.0	11.8	14.5	
9	12.3	15.6	11.1	14.0	
10	11.6	15.0	9.9	12.7	
11	10.6	14.1	9.4	12.3	
12	9.5	13.0	8.7	11.6	
13	8.7	12.2	8.4	11.4	
14	8.5	12.3	7.9	11.0	
15	8.5	12.4	7.1	10.2	<u>.</u>
Median	0.5		0.5		

Table 2b. Observed (obs.) and relative (rel.) survival of patients with Secondary and unspecified sites by sex for period 1998-2020 (N=4,520).




Figure 2c. Conditional relative 2-year survival of patients with Secondary and unspecified sites by sex. For 4,520 of 4,520 cases diagnosed between 1998 and 2020 valid data could be obtained for this item.

Sex						
	Ma	le	Female			
		Cond.	Cond.			
		surv. %	% surv. %			
Years	n	2 yrs	n	2 yrs		
0	2,389	27.2	2,131	25.1		
1	849	59.2	747	55.5		
2	585	73.5	478	72.7		
3	431	84.3	360	82.7		
4	363	88.9	291	92.0		
5	306	90.8	250	93.1		

Table 2d. Conditional relative 2-year survival of patients with Secondary and unspecified sites by sex for period 1998-2020 (N=4,520).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 2a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup sex="Male", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 84.3% (n=431).




Figure 3a. Observed survival of patients with Secondary and unspecified sites by age category. Included in the evaluation are 4,520 cases diagnosed between 1998 and 2020.




Figure 3b. Relative survival of patients with Secondary and unspecified sites by age category. Included in the evaluation are 4,520 cases diagnosed between 1998 and 2020.

			Age	categ	ory			
	0-59	yrs	60-69	9 yrs [–]	70-79	9 yrs	80+	yrs
	n=1,	120	n=1,	149	n=1,	276	n=9	975
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	51.3	51.5	40.4	40.9	29.9	30.8	21.1	23.6
2	36.7	37.0	27.7	28.4	19.8	21.1	13.8	17.0
3	31.3	31.7	21.6	22.5	15.0	16.4	10.2	14.0
4	28.1	28.5	19.2	20.4	12.8	14.7	7.7	12.1
5	26.4	27.0	17.8	19.1	10.7	12.9	6.6	11.7
6	25.7	26.5	16.1	17.6	10.0	12.6	5.9	12.2
7	24.6	25.5	14.8	16.5	8.8	11.5	4.9	11.9
8	23.6	24.7	13.7	15.5	7.8	11.0	3.8	11.4
9	23.2	24.3	13.3	15.4	6.9	10.3		
10	22.2	23.4	11.4	13.6	6.2	10.1		
Median	1.1		0.7		0.4	/	0.2	

Table 3c. Observed (obs.) and relative (rel.) survival of patients with Secondary and unspecified sites by age category for period 1998-2020 (N=4,520).






Figure 4a. Relative survival of patients with Secondary and unspecified sites by extent of disease. For 4,357 of 4,520 cases diagnosed between 1998 and 2020 valid data could be obtained for this item. For a total of 4,356 cases an evaluable classification was established. The grey line represents the subgroup of 164 patients with missing values regarding extent of disease (3.6 % of 4,520 patients, the percent values of all other categories are related to n=4,356). Subgroups with sample size <20 are omitted from the chart.

	Exten	t of di	sease		
	Dist	tant	NA/N	NOS	
	n=4,	349	n=1	64	
Years	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	
1	35.3	36.6	50.9	53.0	
2	24.0	25.5	41.0	43.9	
3	19.0	20.7	34.1	37.9	
4	16.4	18.3	34.1	38.2	
5	14.8	17.0	32.7	37.9	
6	13.9	16.3	31.3	36.8	
7	12.7	15.3	30.5	36.8	
8	11.8	14.5	27.3	34.5	
9	11.1	14.1	26.5	33.3	
10	10.3	13.2	23.7	30.8	
Median	0.5		1.1		

Table 4b. Observed (obs.) and relative (rel.) survival of patients with Secondary and unspecified sites by extent of disease for period 1998-2020 (N=4,356).

Shortcuts

Snortcu	15						
MCR	Munich Cancer Registry, G	ermany					
NCI	National Cancer Institute, USA						
SEER	Surveillance, Epidemiology	, and End Results, USA					
UICC	Union for International Can	cer Control, Geneva					
DCO	Death certificate only	Death certificate provides the only notification to the registry.					
NA	Not available						
NOS	Not otherwise specified						
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause					
RS	Relative survival	Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival					
AS	Assembled survival	Assembled chart of observed, expected, relative survival					
CS	Conditional survival	Survival probability under the condition of surviving a given period of time					
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression					
	1-КМ	1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)					
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)					
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause					

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C76-C80: Secondary and unspecified sites [Internet]. 2022 [updated 2022 Apr 15; cited 2022 Jun 1]. Available from: https://www.tumorregistermuenchen.de/en/facts/surv/sC7680E-ICD-10-C76-C80-Secondary-and-unspecified-sites-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.